Navigation Links
Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
Date:5/21/2009

completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 clinical trials of LymphoStat-B are ongoing, with results expected in July and November 2009.

In January 2009, HGS began delivery of 20,000 doses of ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guara
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc ... the Company has received a complete response letter ... for its New Drug Application (NDA) for the ... the treatment of hypertension.   Photo - ... are disappointed in the receipt of a complete ...
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... PHOENIX, Sept. 4 Zila, Inc.,s (Nasdaq: ZILA ... of,abnormalities which can lead to oral cancer, has been ... of Cetuximab (ERBITUX(R)), a,leading cancer therapeutic for head and ... and distributed by Bristol-Meyers Squibb (NYSE:,BMY). The NIH ...
... Meets Primary and All Secondary Endpoints, San ... NGSX ), a biopharmaceutical company focused on developing ... from,its second pivotal study of NGX-4010, the Company,s ... -- in patients with postherpetic,neuralgia (PHN). The study, ...
Cached Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... P&C Industry Transactions Gateway Multiplies Direct Connectivity with ... States Move to Adopt eBill Regulations CONCORD, ... Property and Casualty industry supplier of EDI Gateway ... providers and payers nationwide. Network expansion enables Jopari ...
... O,Rourke, MD, Associate Professor of Neurosurgery at the University ... to accurately predict the specific genetic mutation that caused ... magnetic resonance imaging (MRI). The researchers presented their findings ... 100th Annual Meeting 2009. , "The field of cancer ...
... in poor areas more of an issue than youngsters, tastes, ... nutrition may be more an issue of supply than demand ... A new study found that children in these rural areas ... research shows these products are not readily available and could ...
... 2009) New research published in the April issue ... Surgeons suggests that, among surgeons inexperienced in laparoscopic ... less time to learn and results in improved outcomes ... with freehand laparoscopy. , Laparoscopic suturing a ...
... April 15, 2009, ten members of the American Society of ... attended more than a dozen meetings scheduled with key Congressional ... of transplant related issues on Capitol Hill. The Fly ... , AST discussed healthcare ...
... In study on rats, protection eludes those exposed as ... and the estrogen hormone they produce might help protect ... caused by the active ingredient in marijuana, Louisiana State ... , The protection did not seem to apply, ...
Cached Medicine News:Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 2Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 3Health News:First noninvasive technique to accurately predict mutations in human brain tumors 2Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 3Health News:AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives 2Health News:Estrogen May Combat Marijuana's Effect on Cognition 2
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: